Form 8-K - Current report:
SEC Accession No. 0001842952-22-000028
Filing Date
2022-03-23
Accepted
2022-03-23 16:06:02
Documents
15
Period of Report
2022-03-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cntx-20220323.htm   iXBRL 8-K 35977
2 EX-99.1 context2021earningsrelease.htm EX-99.1 22206
6 image_0a.jpg GRAPHIC 198753
7 image_1a.jpg GRAPHIC 91002
  Complete submission text file 0001842952-22-000028.txt   612488

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cntx-20220323.xsd EX-101.SCH 1935
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cntx-20220323_lab.xml EX-101.LAB 26869
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cntx-20220323_pre.xml EX-101.PRE 14141
9 EXTRACTED XBRL INSTANCE DOCUMENT cntx-20220323_htm.xml XML 11866
Mailing Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103
Business Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103 267-225-7416
Context Therapeutics Inc. (Filer) CIK: 0001842952 (see all company filings)

IRS No.: 863738787 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40654 | Film No.: 22763236
SIC: 2834 Pharmaceutical Preparations